GLOVER STEPHEN C. received a stock award from AMBRX BIOPHARMA CAYMAN, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 6/9/2023ACC: 0000899243-23-015185
Director
Since May 2023
+142.50K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
3
Total transactions
142.50K acquired
Non-Derivative Transactions1
Ordinary Shares
Direct
Shares
+85K
Price / share
—
Trade value
—
% of position
New position
6/7/2023
0.00→85K
Total
Net shares
+85K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Direct | 6/7/2023 | A · Award | +85K | — | — | New position | 0.00 | 85K |
| Total | +85K | $0.00 | ||||||
Derivative Transactions2
Stock Option (right to buy)
Direct
Converts to
Ordinary Shares
17.50K shares
Shares
+17.50K
Strike price
1.97
Held after
17.50K
Exercisable
—
5/18/2023
Stock Option (right to buy)
Direct
Converts to
Ordinary Shares
40K shares
Shares
+40K
Strike price
1.96
Held after
40K
Exercisable
—
6/7/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Ordinary Shares17.50K shares | 5/18/2023 | A · Award | +17.50K | 1.97 | — | 17.50K |
| Stock Option (right to buy) Direct | Ordinary Shares40K shares | 6/7/2023 | A · Award | +40K | 1.96 | — | 40K |